EKF Diagnostics tightens free float with share buyback and manages major holder’s stake

An update from EKF Diagnostics Holdings ( (GB:EKF) ) is now available.

EKF Diagnostics Holdings has repurchased 156,000 ordinary shares at a volume‑weighted average price of 24.86p, with all shares to be held in treasury, reducing the free float and slightly increasing existing shareholders’ proportional ownership. Following this transaction, EKF’s issued share capital stands at 431,963,112 shares, of which 431,098,112 carry voting rights after accounting for 865,000 treasury shares, a figure that will guide investors’ disclosure calculations under FCA rules.

As part of the buyback, EKF acquired 46,000 shares from funds managed by Harwood to keep non‑executive director Christopher Mills’ aggregate indirect stake at about the same level and below 30% of voting rights. Mills’ indirect holding now totals 127,126,000 shares, with the carefully structured dealing underscoring the company’s attention to UK takeover and transparency thresholds while executing its capital management strategy.

The most recent analyst rating on (GB:EKF) stock is a Hold with a £26.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Spark’s Take on EKF Stock

According to Spark, TipRanks’ AI Analyst, EKF is a Neutral.

EKF Diagnostics Holdings receives a score of 67, driven by strong financial performance and a positive earnings call. The company’s robust balance sheet and improved profitability are significant strengths. However, technical indicators suggest potential bearish momentum, and the valuation is moderate. The positive outlook from the earnings call, including strategic growth plans and a share buyback program, enhances the overall score.

To see Spark’s full report on EKF stock, click here.

More about EKF Diagnostics Holdings

EKF Diagnostics Holdings is an AIM-listed global diagnostics group focused on point‑of‑care analysers in hematology and diabetes, alongside life sciences services that manufacture specialist enzymes and custom products for diagnostic, food and industrial uses. Headquartered near Cardiff, the company runs five manufacturing sites across the U.S. and Germany and sells into more than 120 countries worldwide.

Average Trading Volume: 348,570

Technical Sentiment Signal: Strong Sell

Current Market Cap: £104.9M

See more insights into EKF stock on TipRanks’ Stock Analysis page.